Ainos Business Summary

Ainos, Inc. (AIMD) is a dual-platform technology company specializing in AI-driven scent digitization, branded as "SmellTech," and low-dose interferon therapeutics. The company generates revenue through a "SmellTech-as-a-Service" model, which combines hardware sales of its proprietary AI Nose sensor arrays with high-margin, recurring subscription fees for its Smell Language Model (SLM) and cloud-based analytics. Its primary business segments include Digital Olfaction, targeting industrial automation and semiconductor manufacturing, and Biotechnology, focused on its VELDONA oral interferon platform for autoimmune and infectious diseases. In the competitive landscape, Ainos contends with specialized biotech and medical device firms such as 4D pharma, Alvotech, and Biofrontera; however, it distinguishes itself by pivoting toward industrial AI infrastructure, positioning its digital scent technology as a critical sensing layer for smart factories and robotics that traditional pharmaceutical peers do not address. Leadership is spearheaded by Chairman, President, and CEO Chun-Hsien (Eddy) Tsai, who brings deep technical pedigree as the founder of AI Nose Corporation and Chairman of Taiwan Carbon Nano Technology (TCNT), the company’s largest shareholder. He is supported by CFO Christopher Lee, a CPA with over 25 years of financial experience, including a decade-long tenure as a Nasdaq-listed company executive. The board and founding team are closely integrated with TCNT, leveraging advanced materials expertise to develop the MEMS sensors at the core of their AI Nose platform. Notable institutional backing includes Renaissance Technologies, DRW Securities, and Two Sigma, alongside strategic investment and partnership from ASE Technology Holding Co. (ASEH), the world’s largest semiconductor packaging and testing provider, which serves as a primary anchor customer for Ainos’ industrial scale-up.